Though DSC-MRI perfusion is of well-known benefit for the evaluation of brain tumors, clinical translation has been hampered by a lack of confidence in the consistency of the derived RCBV (relative cerebral blood volume) and cerebral blood flow (CBF) values across sites and platforms. This multi-site and multi-platform study, for which the same patient data set was analyzed, demonstrated substantial consistency in RCBV across software sites and platforms and the ability of each to distinguish low-grade from high-grade tumor. In addition, a single RCBV threshold was identified for which all platforms maintained good accuracy.
This abstract and the presentation materials are available to members only; a login is required.